title: Investigation of prognostic value of polymorphisms within estrogen metabolizing genes in Lithuanian breast cancer patients.
abstract: BACKGROUND
  Breast cancer is the most frequent oncological disease among women. Estrogens are known to play an important role in breast cancer development. Recognition of the relationship between polymorphisms within estrogen metabolizing genes and conventional prognostic factors of breast cancer might improve our knowledge on individualized breast cancer prognosis. Therefore, we aimed to investigate possible associations between germline genetic polymorphisms within GSTM1, GSTT1, GSTP1, SULT1A1 and UGT1A1 genes and breast cancer clinicopathological characteristics together with disease progression.
  
  
  METHODS
  Our study involved 80 young (younger than 50 years of age) breast cancer patients. PCR-based Restriction Fragment Length Polymorphism (RFLP) assay was used to determine GSTP1 and SULT1A1 genotypes. GSTM1 and GSTT1 null genotypes were detected by multiplex PCR. UGT1A1 polymorphism was investigated with microsatellite analysis. Relationships between genotypes and breast cancer clinicopathological features along with disease progression were estimated by Pearson's Chi-square test. Logistic regression analyses were performed to estimate the odds ratios associating different genotypes with clinicopathological characteristics and disease progression.
  
  
  RESULTS
  The study showed individuals with GSTT1 null genotype to have approximately 3.5 times higher risk for breast cancer progression than those with wild type genotype (OR = 3.472, 95% CI 1.043-11.559, P = 0.043). Moreover, SULT1A1 G638A AA genotype significantly increased the chances of HER2 molecular subtype breast cancer when compared to GG genotype (OR = 19.971, 95% CI 1.716-232.480, P = 0.017). Heterozygotes for GSTP1 A313G genotype were more likely to have positive lymph nodes in comparison to AA genotype carriers (OR = 2.803, 95% CI 1.049-7.487, P = 0.040). No significant correlation was determined for UGT1A1 A(TA)nTAA and GSTM1 +/- polymorphism alone or combined GTTT1 null and GSTM1 null genotype.
  
  
  CONCLUSIONS
  Conclusively, our findings suggest that GSTT1 null genotype and SULT1A1 G638A AA genotype could be uselful genetic markers for breast cancer prognosis. Further analyses on larger sample size are required to highlight the effect of GSTP1 G allele on breast cancer prognosis.
authors: Oncology Research Laboratory, Oncology Institute, Lithuanian University of Health Sciences, Eiveniu g. 2 LT-50009, Kaunas, Lithuania. aiste_sav@yahoo.com.
authors: Aistė
authors: A
authors: Savukaitytė
authors: Oncology Research Laboratory, Oncology Institute, Lithuanian University of Health Sciences, Eiveniu g. 2 LT-50009, Kaunas, Lithuania. rasaugenskiene@gmail.com.
authors: Rasa
authors: R
authors: Ugenskienė
authors: Oncology Research Laboratory, Oncology Institute, Lithuanian University of Health Sciences, Eiveniu g. 2 LT-50009, Kaunas, Lithuania. r.jankauskaite@gmail.com.
authors: Roberta
authors: R
authors: Jankauskaitė
authors: Oncology Research Laboratory, Oncology Institute, Lithuanian University of Health Sciences, Eiveniu g. 2 LT-50009, Kaunas, Lithuania. d.cereskevicius@gmail.com.
authors: Darius
authors: D
authors: Čereškevičius
authors: Center of Informatics Technologies, Lithuanian University of Health Sciences, Sukileliu pr. 17 LT-50009, Kaunas, Lithuania. Egle.Sepetauskiene@lsmuni.lt.
authors: Eglė
authors: E
authors: Šepetauskienė
authors: Oncology Institute, Lithuanian University of Health Sciences, Eiveniu g. 2 LT-50009, Kaunas, Lithuania. elona.juozaityte@kaunoklinikos.lt.
authors: Elona
authors: E
authors: Juozaitytė
mesh_terms: D001943:Breast Neoplasms / Q000175:diagnosis* / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D018450:Disease Progression; D004967:Estrogens / Q000378:metabolism*; D005260:Female; D052138:Genes, Neoplasm / Q000235:genetics*; D005838:Genotype; D006801:Humans; D008097:Lithuania; D008875:Middle Aged; D008957:Models, Genetic; D011110:Polymorphism, Genetic; D011379:Prognosis
chemical_list: D004967:Estrogens
references: J Natl Cancer Inst Monogr. 2000;(27):67-73
references: 10963620
references: Ann Oncol. 2012 Jul;23(7):1750-6
references: 22052985
references: Cancer Res. 2001 Oct 1;61(19):7130-5
references: 11585745
references: Cancer Epidemiol Biomarkers Prev. 2001 Dec;10(12):1301-2
references: 11751449
references: Toxicol Lett. 2004 Apr 21;150(2):167-77
references: 15093672
references: Angiogenesis. 2004;7(1):53-8
references: 15302996
references: Eur J Biochem. 1994 Sep 15;224(3):893-9
references: 7925413
references: N Engl J Med. 1995 Nov 2;333(18):1171-5
references: 7565971
references: Lancet. 1996 Mar 2;347(9001):578-81
references: 8596320
references: Biochem Biophys Res Commun. 1997 Oct 9;239(1):298-304
references: 9345314
references: Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10937-42
references: 9380738
references: Pharmacogenetics. 1998 Oct;8(5):441-7
references: 9825836
references: Cancer Lett. 2005 Apr 28;221(2):123-9
references: 15808397
references: Chin Med J (Engl). 2005 Sep 20;118(18):1507-16
references: 16232327
references: Breast Cancer Res. 2005;7(6):R909-21
references: 16280036
references: Mol Biol (Mosk). 2006 Mar-Apr;40(2):263-70
references: 16637266
references: Int Urol Nephrol. 2009;41(2):259-66
references: 18690546
references: Asian Pac J Cancer Prev. 2009 Jan-Mar;10(1):127-32
references: 19469640
references: Breast Cancer Res. 1999;1(1):81-7
references: 11056682